Park Ha Biological Technology Co., Ltd.
BYAH Nasdaq· Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics
KIRA · Stoqly’s AI analyst, in plain words
- Park Ha Biological Technology Co., Ltd. had $2.5M of revenue in fiscal 2025, up 6.0% on the year before.
- Its operating margin was −956.5%, down 989.8 pts: of every 100 in sales, about −956 is left after running the business.
- Park Ha Biological Technology Co., Ltd. lost $24.4M in fiscal 2025.
- Free cash flow was −$0.0M in fiscal 2025, −0.1% of revenue.
Market cap
—
P/E
—
Revenue
$2.5M
Net income
−$24.4M
Free cash flow
−$0.0M
Operating margin
−956.5%
Park Ha Biological Technology Co., Ltd. in 30 seconds · fiscal 2025
Are sales growing?
+6.0%
Yes. Sales grew 6.0% last year.
Does it make a profit?
−965.0%
No. It lost money last year.
Does profit turn into cash?
−0.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
What Park Ha Biological Technology Co., Ltd. does
No business description yet.
- Fiscal year ends
- October 31, 2025
- Latest annual report
- 20-F · Mar 2, 2026
- Legal name
- Park Ha Biological Technology Co., Ltd.
- CIK
- 0001986247
Park Ha Biological Technology Co., Ltd. · BYAH
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | $1.9M | $2.5M | $2.4M | $2.5M |
| Revenue growth | — | 28.1% | −3.1% | 6.0% |
| Gross margin | 73.5% | 87.4% | 91.8% | 94.4% |
| Operating margin | 10.3% | 48.0% | 33.3% | −956.5% |
| Net income | $0.2M | $0.9M | $0.5M | −$24.4M |
| Net margin | 10.0% | 34.6% | 20.1% | −965.0% |
| Diluted EPS | $0.01 | $1.70 | $0.96 | −$41.38 |
| Cash | ||||
| Cash from operations | $1.4M | $0.1M | $1.0M | $0.1M |
| Capital expenditure | $0.0M | $0.0M | $0.1M | $0.1M |
| Free cash flow | $1.4M | $0.1M | $0.9M | −$0.0M |
| FCF margin | 74.5% | 4.2% | 36.7% | −0.1% |
| Share count change | — | −98.0% | 0.0% | 17.8% |
| Debt and strength | ||||
| Cash and short-term investments | $0.6M | $1.0M | $0.5M | $3.8M |
| Shareholders' equity | $0.2M | $1.0M | $1.5M | $4.0M |
| Current ratio | — | 1.8x | 1.9x | 2.9x |
| Interest coverage | 985.0x | — | — | — |
| Returns and quality | ||||
| Return on equity | 127.3% | 146.5% | 38.0% | −885.8% |
| Return on tangible equity | 127.3% | 84.9% | 31.9% | −610.9% |
| Piotroski F-score | — | — | 6 | 4 |
| Altman Z'' | — | 6.9 | 5.8 | −34.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Park Ha Biological Technology Co., Ltd. · BYAH
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Source: SEC EDGAR XBRL filings (CIK 0001986247). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.